Recent Securities Litigations
Teligent Inc. Common Stock (NASDAQ: TLGT)
According to the Complaint, Teligent researches, develops, produces, supplies, and sells generic pharmaceutical products.
The Complaint alleges that during the Class Period, Defendants violated provisions of the Exchange Act by issuing false and misleading statements to investors, including in filings with the U.S. Securities and Exchange Commission ("SEC"). The Complaint alleges that specifically, Defendants made false and/or misleading statements regarding, and/or failed to disclose, product non-conformities in research and development and non-compliance with applicable regulations.